Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.
“We are pleased to be working with XenaCare as our exclusive US marketing and distribution licensee for Cobroxin,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “For the past several months, XenaCare has continued to commit significant time, industry expertise and financial resources towards the launch of Cobroxin. We look forward to working closely with them as they complete the initial roll-out of Cobroxin to retailers across the country,” he added.
Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.
Additional benefits to Cobroxin include:
- All Natural
- More Potent than Morphine
- Long Lasting
“Cobroxin is a unique pain reliever that we believe can help improve the lives of the millions of Americans who are actively seeking a safer and more effective alternative for treating chronic pain,” explained Frank Rizzo, President of XenaCare Holdings, Inc. “We have already committed millions of dollars and industry resources towards the launch of Cobroxin and will continue to do so as we successfully introduce Cobroxin through retailers this fall,” he concluded.
On Monday, Nutra Pharma announced that it had completed submission of final Cobroxin packaging and labeling to the Food and Drug Administration (FDA). This submission was the final step required to begin selling Cobroxin.